Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

NCT04499053 is registered in ClinicalTrials.gov with Georgetown University as lead sponsor.

NCT NCT04499053
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04499053 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
Lead sponsor
Georgetown University
Phase
Phase 2
Overall status
Recruiting
Start date
December 9, 2020
Completion date
December 31, 2027
Enrollment
18 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small cell lung